Hospital Pharmacy Europe

SEPTEMBER 8, 2023

Through a combination of news, clinical updates and thought leadership, as well as in-depth analyses, profiles and case studies, Hospital Pharmacy Europe is an indispensable resource sharing best practice to support and inspire hospital pharmacists across the UK and Europe.

Hospitals 103

Hospitals 103

European Pharmaceutical Review

JANUARY 18, 2023

The first good manufacturing practice (GMP) registration of a UK pharmaceutical facility for high Δ9-tetrahydrocannabinol (THC) cannabis active pharmaceutical ingredient (API) has been granted since the legalisation of medical cannabis in 2018. A new GMP registration is positive news for the sector.

Pharmaceutical Companies 110

Pharmaceutical Companies Pharmaceutical Companies Labelling 110

European Pharmaceutical Review

JANUARY 27, 2023

The UK will be the first country to introduce a tailored framework for the regulation of innovative medicines manufactured at the point where a patient receives care, the Medicines and Healthcare products Regulatory Agency (MHRA) has announced.

Hospitals 91

Hospitals 91

Pharma Times

DECEMBER 6, 2023

The neurological condition currently affects one in 300 people in the UK - News - PharmaTimes

56

56

pharmaphorum

NOVEMBER 3, 2022

Consumer and health organisations in the UK have written to the Trade Secretary Kemi Badenoch, saying a leaked chapter of the proposed UK-India free trade agreement (FTA) could raise the price of medicines used by the NHS. ” The post NGOs claim UK-India free trade deal will raise medicine prices appeared first on. .”

Documentation 85

Documentation 85

Pharma Times

NOVEMBER 14, 2023

The terminal condition currently affects around 5,000 people in the UK - News - PharmaTimes

53

53

Pharma Times

NOVEMBER 27, 2023

The IRP will bring life-saving medicines to UK patients from 1 January 2024 - News - PharmaTimes

52

52

Pharma Times

DECEMBER 7, 2023

The disease is one of the leading causes of cancer deaths in the UK - News - PharmaTimes

53

53

Pharma Times

NOVEMBER 24, 2023

Around 3,200 new cases of cervical cancer are diagnosed in the UK every year - News - PharmaTimes

50

50

European Pharmaceutical Review

MARCH 17, 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) ’s UK Stem Cell Bank is trialling an innovative new robot that grows stem cells. The UK is only the second country where this technology has been tested,” Health and Social Care Secretary Steve Barclay commented.

94

94

pharmaphorum

JANUARY 26, 2023

Guidance on the way pharma companies communicate about prescription medicines has been updated in the UK to cover use of social media channels for the first time. It has drawn up the guidance with the help of the companies, the ABPI, and UK regulator the MHRA.

Communication 105

Communication Documentation 105

Pharma Times

OCTOBER 27, 2023

Around 145,000 people in the UK are living with Parkinson’s disease - News - PharmaTimes

53

53

pharmaphorum

SEPTEMBER 14, 2020

AstraZeneca has resumed UK trials for its coronavirus vaccine, after the country’s medicines regulator gave the all-clear following a safety scare. A UK safety committee has concluded its investigations and recommended to the country’s Medicines and Healthcare products Regulatory Agency (MHRA) that trials are safe to resume.

Vaccines 104

Vaccines Immunization 104

Pharmafile

APRIL 12, 2023

Published date: 12/04/2023 Summary: • Scottish Medicines Consortium decision based on the DESTINY-Breast03 trial results which demonstrated a significant improvement in progression-free survival (PFS) and overall survival (OS) with trastuzumab deruxtecan versus trastuzumab emtansine.

52

52

Pharma Times

NOVEMBER 22, 2023

Prostate cancer is responsible for 12,000 deaths every year in the UK - News - PharmaTimes

51

51

Pharma Times

DECEMBER 19, 2023

In the UK, heart rhythms affect around two million people and can cause sudden death - News - PharmaTimes

46

46

Pharma Times

DECEMBER 1, 2023

Every year, around 55,000 women in the UK are diagnosed with the condition - News - PharmaTimes

49

49

Pharma Times

OCTOBER 18, 2023

UK researchers can apply to receive a share of £3m to set up transdisciplinary networks - News - PharmaTimes

50

50

pharmaphorum

JULY 4, 2022

GSK’s recently-unveiled plan to develop a bioscience cluster close to its main R&D site in Stevenage, UK, has moved closer to fruition, now that the first partners have joined the initiative. The UBS/Reef joint venture were said to be in a contest with UK property group British Land to secure a partnership deal for the project.

119

119

Pharma Times

DECEMBER 5, 2023

Millions of people in the UK are set to benefit from the second wave of funding - News - PharmaTimes

47

47

The Guardian - Pharmaceutical Industry

FEBRUARY 20, 2023

Ian Sample speaks to Guardian science correspondent Nicola Davis about the news that Wegovy, an appetite suppressant popular with celebrities in the US, will soon be sold at UK pharmacies.

57

57

Pharma Times

OCTOBER 18, 2023

Around 700 people in the UK could benefit from the new treatment - News - PharmaTimes

51

51

European Pharmaceutical Review

FEBRUARY 27, 2024

[While she is stepping down from her current role, Dame June shared that she still hopes to contribute] “to patient safety and public health in other ways” “It has been an enormous privilege to have led the MHRA through a time of change which is unprecedented in UK medical products regulation.

Communication 98

Communication Vaccines 98

pharmaphorum

NOVEMBER 29, 2021

The facility at the Harwell Science and Innovation Campus in Oxford has received £215 million in public money since it was announced, and several companies have submitted bids for the VMIC, according to the Financial Times, which said it heard the news from “people briefed on the situation.”

Vaccines 105

Vaccines 105

Pharma Times

OCTOBER 6, 2023

The study used data from 50,000 people in the UK Biobank - News - PharmaTimes

55

55

Pharma Times

OCTOBER 12, 2023

The service will benefit major research and industry projects across the UK - News - PharmaTimes

50

50

Pharma Times

SEPTEMBER 26, 2023

EpiSwitch is designed for men with prostate cancer risk in the UK and is 94% accurate - News - PharmaTimes

51

51

European Pharmaceutical Review

MARCH 10, 2023

million Government grant and is designed to expand the UK’s ability to manufacture new gene and cell therapies. The CBC will help the UK grow its cell and gene therapy industry in a rapidly growing international market.” The state-of-the-art facility was part-funded by a £9.43

Vaccines 128

Vaccines 128

Pharma Times

SEPTEMBER 20, 2023

Around 340,000 to 444,000 people in the UK carry one of nine pathogenic gene variants - News - PharmaTimes

50

50

The Guardian - Pharmaceutical Industry

NOVEMBER 5, 2022

Brexit fallout plus funding fears mean an uncertain prognosis, but the firm should report good news this week Rishi Sunak has vowed to make the UK a “science and technology superpower”, following in the footsteps of prime ministers including David Cameron, who called life sciences the “jewel in the crown” of our economy.

59

59

Pharmaceutical Technology

OCTOBER 3, 2022

The UK National Institute for Health and Care Excellence (NICE) has recommended zanubrutinib (Brukinsa) as an option to treat Waldenstrom’s macroglobulinaemia (WM) patients. Cancer Research UK Policy Development head Kruti Shrotri said: “This decision is good news for people affected by Waldenstrom’s macroglobulinaemia.

Chemotherapy 105

Chemotherapy 105

pharmaphorum

SEPTEMBER 15, 2021

The European Commission is reportedly in advanced discussions with French biotech Valneva about picking up the contract to supply COVID-19 vaccines that was terminated by the UK government this week. That would throw a lifeline to Valneva, which was rocked by the UK’s decision to withdraw from the €1.4

Vaccines 116

Vaccines 116

Pharma Times

OCTOBER 10, 2023

Researchers focused on four of the most common heart conditions in the UK - News - PharmaTimes

48

48

Pharmafile

DECEMBER 20, 2022

Summary: • NICE decision for use in Cancer Drugs Fund based on the first interim analysis DESTINY-Breast03 trial results • Trial results reviewed as part of the NICE submission demonstrated patients treated with trastuzumab deruxtecan had a median progression-free survival (PFS) of 25.1 months compared with 7.2 months for trastuzumab emtansine.

52

52

Pharma Times

SEPTEMBER 12, 2023

million people live with coronary heart disease in the UK - News - PharmaTimes

53

53

pharmaphorum

SEPTEMBER 13, 2021

The UK has terminated its order for up to 190 million doses of a COVID-19 vaccine developed by French biotech company Valneva, accusing it of breaching their supply agreement. billion) contract does provide the UK government with the right to exit the agreement to purchase VLA2001, a purified inactivated SARS-CoV-2 vaccine.

Vaccines 59

Vaccines 59

Pharma Times

OCTOBER 17, 2023

The condition is responsible for 2,200 annual deaths in the UK - News - PharmaTimes

47

47